{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:55:14Z","timestamp":1772852114170,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Meningococcal serogroup B (MenB) is the most common cause of invasive meningococcal disease (IMD) in the United States. The US Advisory Committee on Immunization Practices (ACIP) recommends vaccination of healthy adolescents against MenB based on shared clinical decision-making (Category B recommendation). This survey assessed factors associated with MenB vaccine awareness, utilization, and interest among parents\/guardians of US adolescents.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Survey participants were identified in 2016 through KnowledgePanel\u00ae, an online random sample of US households; population-based weighting methodology was used to ensure data reflected a demographically representative population sample. Adults with \u22651 dependent aged 16\u201319\u2009years were eligible and completed an online questionnaire. Respondents were grouped in terms of MenB vaccination of their child as: 1) vaccinated, 2) intending to vaccinate, 3) MenB vaccine-unaware, or 4) vaccine-aware but not intending to vaccinate. Univariate and multivariate analyses were used to identify factors influencing MenB vaccine awareness and utilization; univariate analyses used the weighted proportion of each group or weighted means, and multivariate analyses used logistic regression models based on the weighted study sample of each group.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Six hundred nineteen parents\/guardians participated, corresponding to 26,266,700 members of the US population after weighting. MenB vaccine awareness was significantly associated with parent race and sex. Specifically, 57% of parents were unaware of MenB vaccines, and there was significantly higher lack of awareness among males and those of Hispanic or non-White ethnicity. In addition, 36% of unaware parents\/guardians were interested in and seeking MenB vaccine information from their healthcare provider (HCP), and there was higher interest among parents of Hispanic ethnicity. \u2018Vaccinated\/intending to vaccinate\u2019 versus \u2018not intending to vaccinate\u2019 and \u2018vaccinated\u2019 versus \u2018intending to vaccinate\u2019 were both strongly associated with whether an HCP had recommended vaccination (odds ratios, 4.81 [95% CI 2.46, 9.35] and 5.66 [95% CI 2.46, 12.87], respectively).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Racial and socioeconomic disparities exist in the awareness and utilization of MenB vaccines among parents\/guardians of US adolescents. HCP discussion and recommendation are critical catalysts for MenB vaccination and underscore the need to accurately interpret and implement the shared clinical decision-making (Category B) recommendation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12889-020-09181-8","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T13:38:34Z","timestamp":1594733914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Parental awareness and utilization of meningococcal serogroup B vaccines in the United States"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-5058","authenticated-orcid":false,"given":"Amit","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Galitsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansour","family":"Fahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"issue":"suppl 2","key":"9181_CR1","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","volume":"30","author":"D Pace","year":"2012","unstructured":"Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(suppl 2):B3\u20139.","journal-title":"Vaccine"},{"key":"9181_CR2","unstructured":"World Health Organization. Immunization, Vaccines and Biologicals. Meningococcal meningitis. [http:\/\/www.who.int\/immunization\/diseases\/meningitis\/en\/]. Accessed 2 July 2020."},{"issue":"2 suppl","key":"9181_CR3","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","volume":"59","author":"F Martin\u00f3n-Torres","year":"2016","unstructured":"Martin\u00f3n-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 suppl):S12\u201320.","journal-title":"J Adolesc Health"},{"issue":"8","key":"9181_CR4","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/cid\/cix993","volume":"66","author":"JR MacNeil","year":"2018","unstructured":"MacNeil JR, Blain AE, Wang X, Cohn AC. Current epidemiology and trends in meningococcal disease-United States, 1996-2015. Clin Infect Dis. 2018;66(8):1276\u201381.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"9181_CR5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/phar.1790","volume":"36","author":"B Atkinson","year":"2016","unstructured":"Atkinson B, Gandhi A, Balmer P. History of meningococcal outbreaks in the United States: implications for vaccination and disease prevention. Pharmacotherapy. 2016;36(8):880\u201392.","journal-title":"Pharmacotherapy"},{"key":"9181_CR6","unstructured":"Centers for Disease Control and Prevention. U.S. Department of Health and Human Services. Enhanced Meningococcal Disease Surveillance Report, 2016 [https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report.pdf]."},{"key":"9181_CR7","unstructured":"World Health Organization. Meningococcal meningitis [http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/meningococcal-meningitis]. Accessed 2 July 2020."},{"issue":"12","key":"9181_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"9181_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1128\/JCM.01322-10","volume":"49","author":"FA Bidmos","year":"2011","unstructured":"Bidmos FA, Neal KR, Oldfield NJ, Turner DP, Ala'Aldeen DA, Bayliss CD. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J Clin Microbiol. 2011;49(2):506\u201312.","journal-title":"J Clin Microbiol"},{"issue":"9","key":"9181_CR10","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3201\/eid1709.101762","volume":"17","author":"DA Ala'aldeen","year":"2011","unstructured":"Ala'aldeen DA, Oldfield NJ, Bidmos FA, Abouseada NM, Ahmed NW, Turner DP, Neal KR, Bayliss CD. Carriage of meningococci by university students, United Kingdom. Emerg Infect Dis. 2011;17(9):1762\u20133.","journal-title":"Emerg Infect Dis"},{"key":"9181_CR11","volume-title":"Plotkin\u2019s Vaccines","author":"DM Granoff","year":"2018","unstructured":"Granoff DM, Pollard AJ, Harrison LH: 39 - Meningococcal Capsular Group B Vaccines. In: Plotkin\u2019s Vaccines (7th Edition). Edited by Plotkin SA, Orenstein WA, Offit PA. Philadelphia: Elsevier; 2018."},{"key":"9181_CR12","unstructured":"De Maria A Jr. Invasive Meningococcal Serogroup B Infection at Smith College: Recommendations for the Five College Consortium https:\/\/www.mass.gov\/files\/documents\/2018\/02\/27\/meningococcaldiseaseadvisory11-30-17.docx. Massachusetts Department of Public Health; 2018."},{"key":"9181_CR13","doi-asserted-by":"crossref","unstructured":"Marshall GS, Dempsey AF, Srivastava A, Isturiz RE. US College Students Are at Increased Risk for Serogroup B Meningococcal Disease. J Pediatric Infect Dis Soc. 2019;9:244\u20137.","DOI":"10.1093\/jpids\/piz024"},{"key":"9181_CR14","volume-title":"Meningococcal group B vaccine","author":"Bexsero","year":"2018","unstructured":"Bexsero. Meningococcal group B vaccine. Sovicille (SI): GSK Vaccines, Srl; 2018."},{"key":"9181_CR15","volume-title":"Meningococcal group B vaccine","author":"Trumenba\u00ae","year":"2018","unstructured":"Trumenba\u00ae. Meningococcal group B vaccine. Philadelphia: Wyeth Pharmaceuticals Inc (a subsidiary of Pfizer Inc); 2018."},{"issue":"RR-2","key":"9181_CR16","first-page":"1","volume":"62","author":"AC Cohn","year":"2013","unstructured":"Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1\u201328.","journal-title":"MMWR Recomm Rep"},{"key":"9181_CR17","unstructured":"Centers for Disease Control and Prevention. U.S. Department of Health and Human Services. Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2018. https:\/\/www.cdc.gov\/vaccines\/schedules\/downloads\/past\/2018-child.pdf."},{"key":"9181_CR18","unstructured":"Centers for Disease Control and Prevention. U.S. Department of Health and Human Services. U.S. Advisory Committee on Immunization Practices (ACIP) Handbook for Developing Evidence-Based Recommendations. Version 1.2 [http:\/\/www.cdc.gov\/vaccines\/acip\/recs\/GRADE\/downloads\/handbook.pdf.]."},{"key":"9181_CR19","unstructured":"Mbaeyi S. Updated ACIP statement for meningococcal vaccination in the United States. Atlanta: Advisory Committee on Immunization Practices (ACIP). June 2019 Meeting: June 27, 2019; 2019."},{"key":"9181_CR20","doi-asserted-by":"crossref","unstructured":"Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine \u2014 Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509\u201313.","DOI":"10.15585\/mmwr.mm6619a6"},{"key":"9181_CR21","doi-asserted-by":"crossref","unstructured":"MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171\u20136.","DOI":"10.15585\/mmwr.mm6441a3"},{"issue":"33","key":"9181_CR22","doi-asserted-by":"publisher","first-page":"718","DOI":"10.15585\/mmwr.mm6833a2","volume":"68","author":"TY Walker","year":"2019","unstructured":"Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Fredua B, Singleton JA, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718\u201323.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9181_CR23","unstructured":"YouTube video. February 2019 ACIP Meeting - Meningococcal Vaccines. July 17, 2017. Volume 29, Issue 4. [https:\/\/www.youtube.com\/watch?v=6ZmOh1SLLKQ]. Accessed 2 July 2020."},{"key":"9181_CR24","unstructured":"C.S. Mott Children's Hospital. Michigan Medicine. National Poll on Children's Health. Mott Poll Report: Parents not keeping up with teen vaccines [https:\/\/mottpoll.org\/sites\/default\/files\/documents\/071717_teenvaccines.pdf]."},{"issue":"5","key":"9181_CR25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.acap.2009.04.004","volume":"9","author":"AF Dempsey","year":"2009","unstructured":"Dempsey AF, Singer D, Clark SJ, Davis MM. Parents' views on 3 shot-related visits: implications for use of adolescent vaccines like human papillomavirus vaccine. Acad Pediatr. 2009;9(5):348\u201352.","journal-title":"Acad Pediatr"},{"key":"9181_CR26","doi-asserted-by":"crossref","unstructured":"Dempsey AF, Singer DD, Clark SJ, Davis MM. Adolescent preventive health care: what do parents want? J Pediatr. 2009;155(5):689\u201394 e681.","DOI":"10.1016\/j.jpeds.2009.05.029"},{"issue":"5","key":"9181_CR27","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1542\/peds.2011-0400","volume":"128","author":"AF Dempsey","year":"2011","unstructured":"Dempsey AF, Schaffer S, Singer D, Butchart A, Davis M, Freed GL. Alternative vaccination schedule preferences among parents of young children. Pediatrics. 2011;128(5):848\u201356.","journal-title":"Pediatrics"},{"key":"9181_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/widm.8","volume":"1","author":"W-Y Loh","year":"2011","unstructured":"Loh W-Y. Classification and regression trees. WIREs Data Mining Knowl Discov. 2011;1:14\u201323.","journal-title":"WIREs Data Mining Knowl Discov"},{"key":"9181_CR29","doi-asserted-by":"crossref","unstructured":"Kempe A, Allison MA, MacNeil JR, O\u2019Leary ST, Crane LA, Beaty BL, Hurley LP, Brtnikova M, Lindley MC, Liang JL, et al. Knowledge and attitudes regarding Category B ACIP recommendations among primary care providers for children. Acad Pediatr. 2018;18(7):763\u20138.","DOI":"10.1016\/j.acap.2018.04.005"},{"issue":"4","key":"9181_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.vaccine.2018.11.078","volume":"37","author":"NE Basta","year":"2019","unstructured":"Basta NE, Becker AB, Li Q, Nederhoff D. Parental awareness of meningococcal B vaccines and willingness to vaccinate their teens. Vaccine. 2019;37(4):670\u20136.","journal-title":"Vaccine"},{"key":"9181_CR31","doi-asserted-by":"crossref","unstructured":"Watkins E, Feemster K. Factors associated with uptake of meningococcus B vaccination after an ACIP Category B recommendation. Open Forum Infect Dis. 2018;5(Suppl 1):S737.","DOI":"10.1093\/ofid\/ofy210.2113"},{"issue":"4","key":"9181_CR32","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.vaccine.2009.10.133","volume":"28","author":"A Dempsey","year":"2010","unstructured":"Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine. 2010;28(4):989\u201395.","journal-title":"Vaccine"},{"issue":"1","key":"9181_CR33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2105\/AJPH.2011.300600","volume":"103","author":"KR Ylitalo","year":"2013","unstructured":"Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus vaccination, and race\/ethnicity in the US National Immunization Survey. Am J Public Health. 2013;103(1):164\u20139.","journal-title":"Am J Public Health"},{"key":"9181_CR34","first-page":"1","volume":"2019","author":"CL Williams","year":"2016","unstructured":"Williams CL, Walker TY, Elam-Evans LD, Yankey D, Fredua B, Saraiya M, Stokley S. Factors associated with not receiving HPV vaccine among adolescents by metropolitan statistical area status, United States, National Immunization Survey-Teen, 2016-2017. Hum Vaccin Immunother. 2019:1\u201311.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"9181_CR35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jadohealth.2013.08.006","volume":"54","author":"SA Bynum","year":"2014","unstructured":"Bynum SA, Staras SA, Malo TL, Giuliano AR, Shenkman E, Vadaparampil ST. Factors associated with Medicaid providers\u2019 recommendation of the HPV vaccine to low-income adolescent girls. J Adolesc Health. 2014;54(2):190\u20136.","journal-title":"J Adolesc Health"},{"key":"9181_CR36","unstructured":"Bart SM, Eberhart M, Feemster K. Impact of a Category B recommendation: meningococcal B (MenB) vaccine uptake among adolescents in Philadelphia County. Toronto: Pediatric Academic Societies; 2018."},{"key":"9181_CR37","unstructured":"Family Practice News. MD edge\u00ae. Family Medicine. Analysis finds inconsistent uptake of meningococcal B vaccines. May 10, 2018 [https:\/\/www.mdedge.com\/familymedicine\/article\/165366\/vaccines\/analysis-finds-inconsistent-uptake-meningococcal-b-vaccines]. Accessed 2 July 2020."},{"issue":"3","key":"9181_CR38","doi-asserted-by":"publisher","first-page":"e20180344","DOI":"10.1542\/peds.2018-0344","volume":"142","author":"A Kempe","year":"2018","unstructured":"Kempe A, Allison MA, MacNeil JR, O\u2019Leary ST, Crane LA, Beaty BL, Hurley LP, Brtnikova M, Lindley MC, Albert AP. Adoption of serogroup B meningococcal vaccine recommendations. Pediatrics. 2018;142(3):e20180344.","journal-title":"Pediatrics"},{"key":"9181_CR39","doi-asserted-by":"crossref","unstructured":"Brady MT. Strength and clarity of vaccine recommendations influence providers\u2019 practice. Pediatrics. 2018;142(3):e20181633.","DOI":"10.1542\/peds.2018-1633"},{"key":"9181_CR40","first-page":"1","volume":"16","author":"L Huang","year":"2019","unstructured":"Huang L, Goren A, Lee LK, Li VW, Dempsey A, Srivastava A. Disparities in healthcare providers\u2019 interpretations and implementations of ACIP\u2019s meningococcal vaccine recommendations. Hum Vaccin Immunother. 2019;16:1\u201312.","journal-title":"Hum Vaccin Immunother"},{"key":"9181_CR41","unstructured":"Centers for Disease Control and Prevention. U.S. Department of Health and Human Services. Vaccines for Children Program (VFC) [https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/index.html]. Accessed 2 July 2020."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-020-09181-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09181-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T23:21:14Z","timestamp":1626218474000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-09181-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9181"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-09181-8","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]},"assertion":[{"value":"8 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants of the study consented their willingness to participate via email. Their decision for participation was voluntary and could be canceled at any time during the study if they decided not to participate. The study protocol was reviewed and approved by Western Institutional Review Board (WIRB), which is an independent institutional review board (IRB Pr. No.: 20162459; IRB Study No.: 1169549). WIRB found that the research met the requirements for a waiver of documentation of consent under 45 CFR 46.117(c)(2).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AD serves on advisory boards for Merck, Pfizer, and Sanofi Pasteur and as a consultant to Pfizer. AS and LH are employees of Pfizer and may hold stock or stock options. AG and MF are employees of Ipsos, who were paid contractors to Pfizer Inc and conducted the survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1109"}}